Germany based caprotec bioanalytics opens US Subsidiary
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
caprotec bioanalytics GmbH announced the opening of its US subsidiary based in Burlington, MA. caprotec Inc. will be responsible for North American sales, marketing and support of caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology and its related products.
caprotec is partnering with Genovative Solutions, LLC in the area of sales and marketing. Genovative’s founder Jeff Protentis is acting as caprotec’s lead agent for North America to intensify promotion and sales of caprotec’s products and services. The company also announced the appointment of Dr. Christian Jurinke as President of its US subsidiary caprotec Inc.
Dr Jurinke, a 12 year veteran of developing and commercializing products for life science ventures, joined caprotec in 2008 to head the company’s key product commercialization and help manage the company’s growing distribution channels. Before joining caprotec Dr. Jurinke most recently served in a number of senior management positions at Sequenom, Inc. in San Diego. “The opening of our US subsidiary is an important milestone in commercializing our CCMS technology,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics.
“We have well-established distribution channels in Europe and Japan. The steadily increasing demand for our products in North America necessitated a US presence as the most effective and efficient strategy.” “Our US subsidiary is now fully operational to serve the North American proteomics research community with our growing family of products,” said Dr. Jurinke.
“Through our US subsidiary we can now rapidly execute the increasing amount of orders, and we are able to expand our operations as demand is increasing.” The company’s caproKits address the needs of the proteomics community as a novel and direct way to investigate interactions of small molecules with proteins and are used to identify protein kinases, cAMP and cGMPbinding proteins, methyl transferases or metallo proteases directly from biological samples.
Additional caproKits for multiple new applications are currently under development. In collaborations with pharmaceutical and biotech companies, caprotec uses its proprietary Capture Compound Mass Spectrometry (CCMS) technology to determine protein profiles of drug interactions to identify drug targets as well as side effect causing off target proteins or to elucidate the mode of action.
caprotec is partnering with Genovative Solutions, LLC in the area of sales and marketing. Genovative’s founder Jeff Protentis is acting as caprotec’s lead agent for North America to intensify promotion and sales of caprotec’s products and services. The company also announced the appointment of Dr. Christian Jurinke as President of its US subsidiary caprotec Inc.
Dr Jurinke, a 12 year veteran of developing and commercializing products for life science ventures, joined caprotec in 2008 to head the company’s key product commercialization and help manage the company’s growing distribution channels. Before joining caprotec Dr. Jurinke most recently served in a number of senior management positions at Sequenom, Inc. in San Diego. “The opening of our US subsidiary is an important milestone in commercializing our CCMS technology,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics.
“We have well-established distribution channels in Europe and Japan. The steadily increasing demand for our products in North America necessitated a US presence as the most effective and efficient strategy.” “Our US subsidiary is now fully operational to serve the North American proteomics research community with our growing family of products,” said Dr. Jurinke.
“Through our US subsidiary we can now rapidly execute the increasing amount of orders, and we are able to expand our operations as demand is increasing.” The company’s caproKits address the needs of the proteomics community as a novel and direct way to investigate interactions of small molecules with proteins and are used to identify protein kinases, cAMP and cGMPbinding proteins, methyl transferases or metallo proteases directly from biological samples.
Additional caproKits for multiple new applications are currently under development. In collaborations with pharmaceutical and biotech companies, caprotec uses its proprietary Capture Compound Mass Spectrometry (CCMS) technology to determine protein profiles of drug interactions to identify drug targets as well as side effect causing off target proteins or to elucidate the mode of action.
